Workflow
Cerebras Systems to Raise $5.55 Billion in Year's Largest U.S. IPO So Far
WSJ· 2026-05-14 08:43
The company, which is backed by OpenAI's Sam Altman, priced its upsized offering of 30 million shares at $185.00 a share. ...
Is Palantir Stock a Generational Buying Opportunity?
The Motley Fool· 2026-05-14 08:38
分析师与机构持仓 - 分析师Parkev Tatevosian未持有新闻中提及的任何股票 [1] - The Motley Fool持有并推荐Palantir Technologies的股票 [1] 利益披露 - 分析师Parkev Tatevosian是The Motley Fool的关联方,并可能因其推广服务而获得报酬 [1] - 分析师的个人意见独立,不受The Motley Fool影响 [1]
AbbVie Inc. (ABBV) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Seeking Alpha· 2026-05-14 08:30
会议背景 - 本次会议为美国银行全球医疗健康大会,在拉斯维加斯举行 [1] - 公司艾伯维的团队出席,包括首席财务官Scott Reents和执行副总裁、首席科学官Roopal Thakkar [2] - 会议主持人为美国银行负责覆盖制药和生物科技行业的研究分析师Jason Gerberry [2] 会议内容 - 会议讨论将混合首席财务官相关问题和研发相关问题 [2] - 分析师认为有许多内容需要探讨 [2]
Sight Sciences, Inc. (SGHT) Presents at Bank of America Global Healthcare Conference 2026 Prepared Remarks Transcript
Seeking Alpha· 2026-05-14 08:30
Co-Founder, President, CEO & Director Presentation Good afternoon. I'm Ray. I'm part of the Medtech research team here at Bank of America, and it's my pleasure to introduce Paul Badawi from Sight Sciences here today. Welcome, Paul. Thanks for being here. Paul Badawi We are an interventional eye care leader. We are active, commercially active in 2 large growing segments in eye care anterior segment, glaucoma and dry eye disease. Glaucoma is the world's leading cause of irreversible blindness and dry eye dise ...
SmartCentres Real Estate Investment Trust (SRU.UN:CA) Shareholder/Analyst Call Transcript
Seeking Alpha· 2026-05-14 08:30
Presentation Mitchell Goldhar Executive Chairman & CEO I want to thank you all for joining us today. This is the Annual General Meeting of the holders of units and special voting units of SmartCentres Real Estate Investment Trust. The meeting will now come to order. Before we begin, kindly turn off your mobile devices. My name is Mitchell Goldhar, and I am the Executive Chairman and Chief Executive Officer of SmartCentres and a trustee. Before we start the formal portion of the meeting, I would like to intr ...
EagleRock Announces Pricing of Initial Public Offering
Businesswire· 2026-05-14 08:29
EagleRock Announces Pricing of Initial Public Offering May 13, 2026 8:29 PM Eastern Daylight Time EagleRock Announces Pricing of Initial Public Offering Share HOUSTON--(BUSINESS WIRE)--EagleRock Land, LLC ("EagleRockâ€), a leading land management royalty company that controls surface acreage in the core of the Permian Basin providing access to land, resources, and infrastructure for critical industries, today priced its initial public offering of 17,300,000 Class A shares representing limited liability comp ...
Birkenstock (NYSE:BIRK) Faces Q2 Earnings Miss and Price Target Adjustment
Financial Modeling Prep· 2026-05-14 08:23
分析师观点与目标价调整 - 分析师Peter McGoldrick于2026年5月13日将Birkenstock的目标价下调至51.00美元 [1] - 目标价调整时公司股价为33.06美元 新目标价仍意味着54.26%的潜在上涨空间 [1] 近期市场反应与股价表现 - 公司第二季度利润未达分析师预期后 股价下跌超过13% [2] - 股价跌至32.44美元 创下52周新低 反映出投资者对其短期业绩和库存上升的担忧 [2] 第二季度财务业绩详情 - 季度每股收益为0.59美元 低于Zacks普遍预期的0.70美元 [3] - 每股收益未达预期幅度约为15.18% 构成负面的业绩意外 [3] - 季度营收约为7.2358亿美元 较上年同期的6.0417亿美元显著增长 [5] 盈利能力面临的压力 - 毛利率从上年同期的57.7%收窄至53.9% [4] - 毛利率下降主要归因于不利的汇率变动、美国关税提高以及来自Crocs等竞争对手的加剧 [4] 业务韧性与全年展望 - 公司重申了2026年全年目标 [5] - 公司预计按固定汇率计算营收将增长13%至15% 这剔除了汇率波动的影响以展示基本业务表现 [5]
Amylyx Pharmaceuticals, Inc. (AMLX) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Seeking Alpha· 2026-05-14 08:20
Sure. So we're very excited about the Phase III readout expected next quarter. Avexitide, our lead asset has been through 5 prior trials, all of which showed highly statistically significant effects on glucose and insulin. And then in the Phase II and Phase IIb, we studied the rate of Level 2 and Level 3 hypoglycemia, which showed quite a strong effect as well. So under that backdrop for the Phase III, our goal is to try to keep as much consistent as we possibly could. So very similar inclusion/exclusion cr ...
Absci (NASDAQ: ABSI) Insider Buys Shares Amidst Financial Challenges and Clinical Progress
Financial Modeling Prep· 2026-05-14 08:16
Despite the revenue shortfall, Absci posted a smaller-than-expected loss. The company's quarterly loss was $0.19 per share, which was an improvement over the estimated loss of $0.20 per share. This also compares favorably to the loss of $0.21 per share from the same quarter last year, indicating some progress in managing operational costs and improving earnings per share (EPS). The director's confidence may be linked to operational progress and clinical development. As highlighted by GlobeNewswire, Absci su ...
BTU Investors Have Opportunity to Join Peabody Energy Corporation Fraud Investigation with the Schall Law Firm
Globenewswire· 2026-05-14 08:16
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics. LOS ANGELES, May 13, 2026 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Peabody Energy Corporation ("Peabody" or "the Company") (NYSE: BTU) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or ...